Literature DB >> 2484701

Oxygen and oxidation promote the release of nitric oxide from sydnonimines.

H Bohn1, K Schönafinger.   

Abstract

The antianginal effect of sydnonimines is believed to be due to the release of nitric oxide (NO) from inactive prodrugs. The first step in the transformation of the sydnonimine SIN-1 is the hydroxyl ion-dependent conversion to SIN-1A that occurs almost immediately at neutral pH. However, the subsequent process of NO release from SIN-1A is not yet understood. Therefore, the spontaneous degradation of SIN-1A in aqueous solutions was studied by chemical and pharmacological means. Measurement of the oxygen content of a freshly prepared SIN-1A solution revealed a rapid decrease of the oxygen concentration. The oxygen-consuming process was accompanied by a decrease in SIN-1A concentration and a progressive formation of NO and SIN-1C. SIN-1A was stable under nitrogen, labile under air, and very unstable under pure oxygen. Thus, oxygen is an important reactant in the decomposition of SIN-1A. The question of whether or not oxygen is essential for NO release was studied by investigating the effect of other oxidants. The oxidants potassium hexacyanoferrate, cupric sulfate, and lead tetraacetate augmented the conversion of SIN-1A to SIN-1C and increased the relaxing effect on isolated pulmonary arteries used to bioassay NO. Therefore, an oxidative process is essential for the release of NO from sydnonimines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2484701

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Influence of redox compounds on nitrovasodilator-induced relaxations of rat coronary arteries.

Authors:  M E Murphy
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

2.  Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in man.

Authors:  H Sinzinger; F Rauscha; J O'Grady; P Fitscha
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

3.  Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system.

Authors:  K E Wiley; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 4.  Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature.

Authors:  H E Wegner; H H Knispel; T Meier; R Klän; K Miller
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

5.  Vasorelaxant and antiaggregatory properties of the endothelium: a comparative study in normocholesterolaemic and hereditary and dietary hypercholesterolaemic rabbits.

Authors:  C Greenlees; C L Wainwright; R M Wadsworth
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

6.  Enzymic and nonenzymic release of NO accounts for the vasodilator activity of the metabolites of CAS 936, a novel long-acting sydnonimine derivative.

Authors:  A Mülsch; M Hecker; P I Mordvintcev; A F Vanin; R Busse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-01       Impact factor: 3.000

7.  In vitro studies of interactions of NO. donor drugs with superoxide and hydroxyl radicals.

Authors:  F Dalloz; V Maupoil; S Lecour; F Briot; L Rochette
Journal:  Mol Cell Biochem       Date:  1997-12       Impact factor: 3.396

8.  Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor.

Authors:  H Bohn; J Brendel; P A Martorana; K Schönafinger
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

9.  Interleukin 1beta decreases prostacyclin synthase activity in rat mesangial cells via endogenous peroxynitrite formation.

Authors:  M H Zou; T Klein; J P Pasquet; V Ullrich
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

10.  Effect of the molsidomine metabolite SIN-1 on coronary arteries and peripheral vessels of sheep with special reference to tolerance and endothelium.

Authors:  M H Yousif; F Yousif; O Thulesius
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.